Iantrek Publishes New Data on AlloFlo Uveo

Iantrek has announced the publication of two new peer-reviewed studies, expanding the body of clinical evidence supporting its bio-reinforced cyclodialysis implant, AlloFlo Uveo. With these additions, the total number of peer-reviewed publications on AlloFlo Uveo rises to seven, reflecting growing interest and validation in the ophthalmology community.

Systematic Review Highlights Clinical Outcomes of Cyclodialysis

The first study, published in Clinical Ophthalmology, presents Level I clinical evidence through what Iantrek describes as the largest systematic review and meta-analysis of ab-interno uveoscleral outflow enhancement procedures to date. This comprehensive analysis incorporates data from more than 4,000 eyes across 40 cyclodialysis studies, covering over a century of surgical experience.

Lead author Robert Stamper, MD, Professor of Ophthalmology at UCSF, commented:

“The analysis confirms cyclodialysis as an effective procedure for enhancing uveoscleral outflow, with modern ab-interno approaches showing improved intraocular pressure (IOP)-lowering efficacy, safety, and durability.”

One-Year Prospective Data Supports Real-World Effectiveness

The second study presents 1-year prospective outcomes in 51 eyes with uncontrolled primary open-angle glaucoma treated using AlloFlo Uveo. Results highlight significant improvements in both pressure control and medication burden:

• Intraocular pressure (IOP) reduction from 25.7 mmHg at baseline to 15.4 mmHg at 12 months, representing a 40% relative decrease

• A 42% reduction in the number of IOP-lowering medications required at 1 year

According to Iantrek, these findings add to the growing body of evidence established by the ongoing CREST Study, further supporting the clinical value of AlloFlo Uveo in glaucoma management.

Commercial Launch Planned at AAO 2025

Iantrek is preparing for the formal commercial launch of AlloFlo Uveo at the upcoming American Academy of Ophthalmology (AAO) annual meeting. The company reports that nearly 3,000 procedures using AlloFlo Uveo have already been performed in the United States, indicating early clinical adoption.

Commenting on the clinical momentum, Arsham Sheybani, MD, of Washington University in St. Louis, noted:

“The growing body of peer-reviewed evidence represents an important step in glaucoma care. Patients should have access to a full range of surgical options, including approaches that engage the uveoscleral pathway. Supported by real-world evidence data from the CREST Study, AlloFlo Uveo appears to be a valuable addition to our surgical armamentarium.”